Folate targeting

Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results

Retrieved on: 
Tuesday, May 2, 2023
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Molecule, SEQUOIA, Arrowhead, Volunteering, GSK, Idiopathic pulmonary fibrosis, Asthma, Central nervous system, NASH, Takeda, Triglyceride, Clinical trial, Folate targeting, Brain, Research, Part, CNS, Trial of the century, PIN, Outline, Patient, PNPLA3, Fatty liver disease, Webcast, RNA interference, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Janssen Pharmaceuticals, Food, Pharmaceutical industry, Vaccine, C3

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023.
  • The company is hosting a conference call today, May 2, 2023, at 4:30 p.m.
  • Reported interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE, an investigational RNAi therapeutic for treatment for inflammatory pulmonary diseases, such as asthma.
  • Key results from Part 1 of the study in normal healthy volunteers included the following:
    These results include 4 of 5 escalating dose levels.

Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect

Retrieved on: 
Tuesday, April 25, 2023
Health, Hospitals, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Molecule, Arrowhead, Interim, Critical care, RAGE, Asthma, University, Folate targeting, University of Kansas Health System, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., RNA, Trial of the century, Arrowhead Pharmaceuticals, Patient, University of Kansas Medical Center, RNA interference, Research, Safety, Pharmaceutical industry

These data represent the first clinical demonstration of the potential utility of Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform optimized for delivery to the lungs.

Key Points: 
  • These data represent the first clinical demonstration of the potential utility of Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform optimized for delivery to the lungs.
  • Matthias Salathe, M.D., Professor, Pulmonary, Critical Care and Sleep Medicine, and Vice Chancellor for Research at the University of Kansas Medical Center, said: “These interim ARO-RAGE Phase 1/2 data are highly encouraging.
  • Unmet need continues to exist for many patients with severe asthma who suffer from persistent symptoms and exacerbations, despite current therapies.
  • The high level of target gene knockdown, the long duration of effect, and the promising safety and tolerability results are all very encouraging signs for our growing pipeline of RNAi therapeutic candidates that leverage this same platform.

Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Stem cell, Society, Conjugation, Magenta, U.S. Securities and Exchange Commission, Clinical trial, Program, Transplant, Disclosure, Stem cell factor, Food, Sickle cell disease, Pharmacodynamics, GLOBE, ASH, Toxic epidermal necrolysis, Phenotype, Safety, PD, GVHD, Security (finance), Degenerative disease, Control, Patient, Blood, Genetic distance, MDS, Leadership, ADC, B cell, Bone marrow, Biotechnology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NHP, Private Securities Litigation Reform Act, Folate targeting, COVID-19, Abstract (summary), Goal, Survival, Primate, CD117, CD137, Microdeletion syndrome, Cell, Uncertainty, Therapy, Growth hacking, Toxicology, Engineering, Lymphatic system, AML, PK, Pharmaceutical industry, Vaccine, Pharmacokinetics

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will make three presentations relating to its ongoing clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting, to be held in New Orleans from December 10-13, 2022 and virtually. In addition, an academic collaborator will present data from a preclinical program from Magenta’s research platform.

Key Points: 
  • In addition, an academic collaborator will present data from a preclinical program from Magentas research platform.
  • CD117, also known asc-Kit receptor, is highly expressed on hematopoietic stem cells, progenitor cells, and leukemic cells.
  • As described separately, in addition to the results described in the published abstract, Magenta will present updated available clinical data.
  • Magenta explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.

AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

Retrieved on: 
Friday, September 16, 2022
Autoimmunity, Therapy, Organic, Psoriasis, Folate targeting, IND, Company, News, Private Securities Litigation Reform Act, Patient, CEO, Ulcerative colitis, Chief executive officer, SAN, Biotechnology, Inflammation, GLOBE, Pharmaceutical industry

SAN FRANCISCO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (AltruBio or the Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced that AltruBio President and CEO Dr. Judy Chou will speak on The Next Wave of Targeted Therapies at the Longwood Healthcare Leaders Fall Webconference on Wednesday, September 21, 2022.

Key Points: 
  • SAN FRANCISCO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (AltruBio or the Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced that AltruBio President and CEO Dr. Judy Chou will speak on The Next Wave of Targeted Therapies at the Longwood Healthcare Leaders Fall Webconference on Wednesday, September 21, 2022.
  • To learn more about the event, view the agenda, and request an invitation, visit www.longwoodhealthcareleaders.com .
  • AltruBio is a privately held biotechnology company headquartered in San Francisco that is focused on developing novel therapeutics for the treatment of immunological diseases with high unmet medical needs.
  • The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Retrieved on: 
Thursday, August 11, 2022
EHA, U.S. Securities and Exchange Commission, ESMO, Interim, European Society for Medical Oncology, University, GT, Accounting, GLOBE, R, Growth, Investment, Folate targeting, NK, IND, Director, Board, Congress, Knowledge, Security (finance), Research and development, Patient, Camelidae, Company, Therapy, Form 10-K, Audit committee, G&A, NASDAQ, General officer, Research, Goal, Oncology, Annual report, Administration, Consultant, Investigational New Drug, Vaccine, Audit, Fine chemical

BRISBANE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company or GTB) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced second quarter fiscal 2022 results for the period ended June 30, 2022.

Key Points: 
  • BRISBANE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company or GTB) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced second quarter fiscal 2022 results for the period ended June 30, 2022.
  • We are building a strong portfolio of knowledge across GT Biopharmas TriKE product candidates through investigation of preclinical solid tumor and hematological cancers models.
  • Mr. Alan Urban a member of the Board of Directors has assumed the role of financial expert of the Audit Committee.
  • GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics

Retrieved on: 
Thursday, May 26, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Molecule, Inflammation, Risk, Mission statement, RNA transfection, International Congress on Tuberculosis, Company, European Respiratory Society, R, MUC5AC, Private Securities Litigation Reform Act, Toxicology, Gene, U.S. Securities and Exchange Commission, Arrowhead Pharmaceuticals, University of Kansas Medical Center, News, Patient, Asthma, NASDAQ, RNA interference, GLP, MPH, COVID-19, Investor, MMP7, Mouse, RATS, Literature, Primate, Fibrosis, RAGE, Folate targeting, Program, RNA, Safety, University, Gene silencing, Lung, Therapy, Pharmacodynamics, Sirna, Twitter, ERS, IPF, Pulmonary fibrosis, Overload, Security (finance), Annual report, Pharmaceutical industry, Arrowhead

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform.
  • A live and archived webcast of the event may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
  • The pulmonary targeted TRiMTM platform has come a long way since our first clinical candidate, ARO-ENaC.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Orphagen Pharmaceuticals Presents Preclinical Efficacy Data at AACR 2022 on OR-449, a First-in-Class Steroidogenic Factor 1 Inhibitor, for the Treatment of Leydig Cell Tumors

Retrieved on: 
Friday, April 8, 2022
Technology, Research, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, ENDO, Cancer, PDX, ACC, IC50, Section 27 of the Canadian Charter of Rights and Freedoms, Squamous cell carcinoma, DNA, Diagnosis, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Leydig cell tumour, Folate targeting, Mouse, LCT, IND, SF-1, AACR, Program, American Association, Incidence, CEO, Tissue, Poster, Autoimmune disease, Immunodeficiency, Testicular cancer, Association, American Association for Cancer Research, New Orleans Morial Convention Center, HEK293, NIH, Crowe, RNA transfection, Doctor of Philosophy, LCT 7074, NR5A1, Founder, Patient, Radiation, Pharmaceutical industry, Vaccine, R2C

The data presented at AACR 2022 demonstrate that OR-449, a potent SF-1 antagonist, has clear potential for clinical efficacy in malignant LCTs as well as ACC.

Key Points: 
  • The data presented at AACR 2022 demonstrate that OR-449, a potent SF-1 antagonist, has clear potential for clinical efficacy in malignant LCTs as well as ACC.
  • The incidence of ACC in the U.S. is 300 patients per year, and existing therapies are very limited.
  • Testicular cancer is in turn one of the most frequently diagnosed cancers in American males between the ages of 15 and 35.
  • Orphagen has initiated IND-enabling studies of OR-449 with an anticipated IND-filing date at the end of 2022.

Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Immunoglobulin A, Therapy, IgA nephropathy, RNA, CKD, NASDAQ, Folate targeting, LDHA, Kidney, Trial of the century, Atrasentan, Chronic kidney disease, TNF, Patient, Survival, Primary hyperoxaluria, Pharmaceutical industry, Online gambling, Chinook

SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 4th Annual Chronic Kidney Disease Drug Development (CKD) Summit in Boston from March 1 - 3, 2022.

Key Points: 
  • SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 4th Annual Chronic Kidney Disease Drug Development (CKD) Summit in Boston from March 1 - 3, 2022.
  • Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases.
  • Chinooks product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways.
  • Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.